Why Blackbaud (BLKB) is a Top Growth Stock for the Long-Term

In this article:

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why This 1 Growth Stock Should Be On Your Watchlist

For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time.

Blackbaud (BLKB)

Headquartered in Charleston, SC, Blackbaud Inc. is a leading cloud software company working for social causes. The company combines technology and expertise to help organizations achieve their missions.

BLKB sits at a Zacks Rank #3 (Hold), holds a Growth Style Score of A, and has a VGM Score of B. Earnings and sales are forecasted to increase 40.9% and 4.8% year-over-year, respectively.

One analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0 to $3.79 per share for 2023. BLKB boasts an average earnings surprise of 10.6%.

On a historic basis, Blackbaud has generated cash flow growth of 0.9%, and is expected to report cash flow expansion of 16.8% this year.

With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, BLKB should be on investors' short lists.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Blackbaud, Inc. (BLKB) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement